Description
Author discusses paroxetine, an antidepressant manufactured by GlaxoSmithKline, its use in adolescents, the controversy over Study 329, and the company's continued reticence to share all of its clinical trial data.Citation
Doshi, P. (2013). Putting GlaxoSmithKline to the test over paroxetine. BMJ, 347. DOI: 10.1136/bmj.f6754Keyword
research transparencyRestoring Invisible and Abandoned Trials
RIAT
Study 329
GlaxoSmithKline
Access to Information
Adolescent
Clinical Trials as Topic
Depression
Paroxetine
Identifier to cite or link to this item
http://hdl.handle.net/10713/6614ae974a485f413a2113503eed53cd6c53
10.1136/bmj.f6754
Scopus Count
Collections
Related articles
- Spitzer sues drug giant for deceiving doctors.
- Authors: Wadman M
- Issue date: 2004 Jun 10
- GlaxoSmithKline faces US lawsuit over concealment of trial results.
- Authors: Dyer O
- Issue date: 2004 Jun 12
- Is GSK guilty of fraud?
- Authors: Lancet
- Issue date: 2004 Jun 12
- Compounding risks to patients: selective disclosure is not an option.
- Authors: McGoey L
- Issue date: 2009 Aug
- Reputations at stake.
- Issue date: 2002 Mar 16